----- 消化不良
Dyspepsia in particular remains a complex problem in clinical practice once an organic cause is excluded. Many recent attempts to find new treatment strategies have failed: Tegaserod, for example, has been withdrawn from the United States, and itopride, which showed promising results in phase 2 trials, ultimately failed in phase 3 trials. Future treatments will depend to a significant extent on the careful evaluation of patients and an analysis of their symptoms, as well as on new insights into the pathophysiology of symptoms in the upper GI tract. This publication provides an overview of the current state of dyspepsia diagnosis and management, evaluating the pathophysiology, current diagnostic and treatment strategies, as well as the results of 'Helicobacter pylori' eradication and proton pump inhibitor therapy. Moreover, future options for therapy of this common disorder are assessed, making this compilation a most welcome reference work for the clinician.
{{comment.content}}